Company intelligence / Profile preview

Neurimmune

Zurich-Schlieren, Switzerlandneurimmune.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Neurimmune has advanced multiple antibody programs into clinical development, including ALXN2220/NI006 for ATTR cardiomyopathy, which is in Phase 3 and has received FDA Fast Track designation. Aducanumab, developed with Biogen for Alzheimer’s disease, reached commercial stage. Other programs are at various stages from preclinical to early clinical trials[2][5].

Therapeutic areas: EndocrinologyCardiovascularNeurology
Modalities: Monoclonal antibodySmall moleculeGene therapy (vectorized human antibodies)
Industry: Biotech

Drug pipeline

3 assets

NI101B3

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

BiogenAstraZeneca/Alexion PharmaceuticalsOno PharmaceuticalEli Lilly Chorus unitTVM Capital

Beyond the preview

Go deeper on Neurimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurimmune.

Explore the full profile